Zurcher Kantonalbank (Zurich Cantonalbank) Zentalis Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$4.09 - $16.13 $31,938 - $125,959	-7,809 Reduced 50.0%	7,809 $31,000
Q1 2024 Apr 25, 2024	BUY	$10.83 - $16.49 $84,571 - $128,770	7,809 Added 100.0%	15,618 $246,000
Q2 2023 Aug 07, 2023	BUY	$17.41 - $30.05 $32,835 - $56,674	1,886 Added 31.84%	7,809 $220,000
Q1 2023 May 08, 2023	SELL	$16.14 - $24.94 $5,955 - $9,202	-369 Reduced 5.86%	5,923 $101,000
Q2 2022 Aug 09, 2022	BUY	$17.91 - $52.25 $106,080 - $309,476	5,923 Added 1605.15%	6,292 $177,000
Q1 2022 Apr 21, 2022	SELL	$41.58 - $80.89 $27,401 - $53,306	-659 Reduced 64.11%	369 $17,000
Q4 2021 Feb 01, 2022	SELL	$66.92 - $84.79 $5,688 - $7,207	-85 Reduced 7.64%	1,028 $86,000
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $702 - $1,102	15 Added 1.37%	1,113 $74,000
Q2 2021 Jul 30, 2021	BUY	$37.41 - $62.25 $4,564 - $7,594	122 Added 12.5%	1,098 $58,000
Q1 2021 May 03, 2021	BUY	$35.69 - $52.72 $34,833 - $51,454	976 New	976 $42,000

Others Institutions Holding ZNTL

# of Institutions

138

Shares Held

68.1M

Call Options Held

48.5K

Put Options Held

89.6K

Matrix Capital Management Company, LP Waltham, MA

14M
Shares

$29.9 Million
2.45% of portfolio
Eventide Asset Management, LLC Boston, MA

8.55M
Shares

$18.3 Million
0.55% of portfolio
Black Rock Inc. New York, NY

4.82M
Shares

$10.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.61M
Shares

$9.87 Million
0.0% of portfolio
Decheng Capital LLC Menlo Park, CA

3.11M
Shares

$6.65 Million
2.71% of portfolio

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $122M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account